S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:BMRN

BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

$91.24
+1.27 (+1.41%)
(As of 02/23/2024 ET)
Today's Range
$89.48
$94.15
50-Day Range
$86.01
$99.00
52-Week Range
$76.02
$103.58
Volume
3.65 million shs
Average Volume
1.34 million shs
Market Capitalization
$17.19 billion
P/E Ratio
103.68
Dividend Yield
N/A
Price Target
$109.74

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
20.3% Upside
$109.74 Price Target
Short Interest
Healthy
1.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.51mentions of BioMarin Pharmaceutical in the last 14 days
Based on 39 Articles This Week
Insider Trading
Selling Shares
$4.56 M Sold Last Quarter
Proj. Earnings Growth
31.84%
From $2.23 to $2.94 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

14th out of 943 stocks

Pharmaceutical Preparations Industry

7th out of 429 stocks


BMRN stock logo

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock Price History

BMRN Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Stifel Nicolaus Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
The Latest Analyst Ratings For Biomarin Pharmaceutical
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Q4 2023 Biomarin Pharmaceutical Inc Earnings Call
BioMarin Pharmaceutical (BMRN) Set to Announce Earnings on Thursday
BMRN Mar 2024 95.000 put
BMRN Jul 2024 80.000 call
BMRN Jan 2025 130.000 put
BMRN Mar 2024 125.000 call
BMRN Mar 2024 85.000 put
BMRN Apr 2024 70.000 call
3 Biotech Stocks Making Major Moves on Wall Street
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
2/24/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,082
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$109.74
High Stock Price Target
$185.00
Low Stock Price Target
$78.00
Potential Upside/Downside
+20.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
20 Analysts

Profitability

Net Income
$141.56 million
Pretax Margin
6.56%

Debt

Sales & Book Value

Annual Sales
$2.42 billion
Cash Flow
$1.49 per share
Book Value
$24.82 per share

Miscellaneous

Free Float
184,902,000
Market Cap
$17.19 billion
Optionable
Optionable
Beta
0.31

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report














BMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price target for 2024?

20 Wall Street analysts have issued 12-month price targets for BioMarin Pharmaceutical's shares. Their BMRN share price targets range from $78.00 to $185.00. On average, they anticipate the company's share price to reach $109.74 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2024?

BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of 2024. Since then, BMRN stock has decreased by 5.4% and is now trading at $91.24.
View the best growth stocks for 2024 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 3,170,000 shares, a drop of 7.3% from the January 15th total of 3,420,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is presently 1.9 days.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.05. The biotechnology company had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 5.06% and a net margin of 6.93%. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of 2.600-2.800 for the period, compared to the consensus estimate of 1.960. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.78%), Vanguard Group Inc. (9.58%), Dodge & Cox (7.43%), Capital Research Global Investors (5.72%), Viking Global Investors LP (2.60%) and Avoro Capital Advisors LLC (2.28%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMRN) was last updated on 2/24/2024 by MarketBeat.com Staff